Author | Feng Cai

Feng Cai, MSc/MBAis a contract scientist for Elan Pharmaceuticals in Princeton, NJ.

Articles

Pharmaceutical Executive

Risks and Rewards for Pharma in Post-WTO China

New markets are a pharmaceutical company's dream. And China, with a population of 1.3 billion-and new membership in the World Trade organization-could be the pharma industry's dream come true. The country's projected growth rate of 1.1 percent per year, which will increase its pharma market by at least $50 million annually, in addition to an increasingly prosperous population with a greater awareness of health-related issues, make the market extremely attractive. (See "People Power,")